{
  "id": "6023415b1cb411341a00008c",
  "type": "summary",
  "question": "What is the mechanism of action of Evinacumab?",
  "ideal_answer": "Evinacumab is a monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3) that has been shown to reduce low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33295805",
    "http://www.ncbi.nlm.nih.gov/pubmed/34698927",
    "http://www.ncbi.nlm.nih.gov/pubmed/32813947",
    "http://www.ncbi.nlm.nih.gov/pubmed/34713869",
    "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
    "http://www.ncbi.nlm.nih.gov/pubmed/32492513",
    "http://www.ncbi.nlm.nih.gov/pubmed/31578082",
    "http://www.ncbi.nlm.nih.gov/pubmed/32841138",
    "http://www.ncbi.nlm.nih.gov/pubmed/34253139",
    "http://www.ncbi.nlm.nih.gov/pubmed/31843957",
    "http://www.ncbi.nlm.nih.gov/pubmed/34585515",
    "http://www.ncbi.nlm.nih.gov/pubmed/30011918",
    "http://www.ncbi.nlm.nih.gov/pubmed/32511037",
    "http://www.ncbi.nlm.nih.gov/pubmed/34327869",
    "http://www.ncbi.nlm.nih.gov/pubmed/33278127",
    "http://www.ncbi.nlm.nih.gov/pubmed/31242752"
  ],
  "snippets": [
    {
      "text": "Current therapies reduce plaque volume, but targeting all apoB-containing lipoproteins with intensive combinations that include alirocumab or evinacumab, monoclonal antibodies against cholesterol-regulating proprotein convertase subtilisin/kexin type 9 and angiopoietin-like protein 3, may provide more benefit. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31843957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, regarding TG a monoclonal antibody called evinacumab and an antisense-oligonucleotide against ANGPTL3 showed effective TG-lowering.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32492513",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Multiple ANGPLT3 inhibitors (evinacumab, IONIS-ANGPTL3-LRx, ARO-ANG3) effectuate TG reductions up to 70% with concomitant potent reduction in all other apoB containing lipoprotein fractions. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511037",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32813947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include an antisense oligonucleotide against apoC-III (volanesorsen), a monoclonal antibody against angiopoietin-like protein-3 (evinacumab), and other agents currently in development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32841138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND AND AIMS: Evinacumab, an angiopoietin-like protein 3 monoclonal antibody, reduced low-density lipoprotein cholesterol (LDL-C) significantly in a Phase 2 study of patients with homozygous familial hypercholesterolemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab, a novel monoclonal antibody against angiopoetin-like 3 (ANGPTL3), reduces LDL-C by 50% independent of LDLR activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33278127",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Modifications included the addition of intermediate-density lipoprotein and low-density lipoprotein compartments to address the modulation of lipoprotein lipase (LPL) activity by evinacumab, ANGPTL3 biosynthesis and clearance, and a target-mediated drug disposition model.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34327869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nversely, evinacumab, the mAb targeting ANGPTL3, is highly effective in reducing LDL-C levels even in HoFH patients carrying null LDLR mutations, thanks to its LDLR-independent mechanism of action. M",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34698927",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A model to quantitatively characterize the effect of evinacumab, an investigational monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3) on lipid trafficking is needed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34327869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "lipids. Evinacumab, an ANGPTL3 inhibitor, reduced triglycerides in healthy human volunteers and in homozygous familial hypercholesterolemic indiv",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31242752",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, has been shown to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). This",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585515",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholest",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32813947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ry atherosclerosis. Evinacumab, a fully human monoclonal antibody, inhibits ANGPTL3 and reduces multiple lipoprotein fractions ~50%,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34253139",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e I clinical trials with a monoclonal anti-ANGPTL3 antibody (evinacumab) and anti-sense oligonucleotide (ASO) clearly show a significant lipid lowering effect. In addition, from t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30011918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "er306Leu). Evinacumab had no effect on LDLR activity.CONCLUSIONS: These results suggest that evinacumab is effective for lowering LDL-C in patients with homozygous familial hypercholesterolemia, and the inhibition of ANGPTL3 in humans lowers LDL-C in a mechanism ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31578082",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab is a human monoclonal antibody which binds and inhibits angiopoietin-like protein 3 (ANGPTL3).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34713869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, has been shown to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585515",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "her lipids. Evinacumab, an ANGPTL3 inhibitor, reduced triglycerides in healthy human volunteers and in homozygous familial hypercholesterolemic ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31242752",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND AIMS: Evinacumab, an angiopoietin-like protein 3 monoclonal antibody, reduced low-density lipoprotein cholesterol (LDL-C) significantly in a Phase 2 study of patients with homozygous familial ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ar disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia.METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) ever",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32813947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "n HoFH bearing defective mutations. Conversely, evinacumab, the mAb targeting ANGPTL3, is highly effective in reducing LDL-C levels even in HoFH patients carrying null LDLR mutations, thanks to its L",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34698927",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab, a fully human monoclonal antibody, inhibits ANGPTL3 and reduces multiple lipoprotein fractions ~50%, including LDL-C.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34253139",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evinacumab is a human monoclonal antibody inhibitor of angiopoietin-like protein 3 (ANGPTL3).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33295805",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "r disease. A phase 2, proof-of-concept study (NCT02265952) demonstrated that evinacumab, a fully human monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein), reduced LDL-C levels in 9 patients with genotypically confirmed homozygous familial hypercholesterolemia and was well",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31578082",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}